Skip to main content

Table 1 Summary of phage pharmaceutical and their phage-based product

From: Phage therapy as a revolutionary medicine against Gram-positive bacterial infections

Name of the pharmaceuticals/centers Location Target Gram-positive pathogen Name of the phage product Platform Product approval agent Objective
Pherecydes Pharma France Staphylococcus aureus PHOSA Phage cocktail N/A To treat infections of bone and joint or diabetic foot ulcer infections
Armata Pharmaceuticals USA Staphylococcus aureus, Streptococcus mutans AP-SA02 Synthetic phages FDA They use synthetic phages in which phage are engineered to express C16G2 antimicrobial peptide for treating tooth decays caused by S. aureus and S. mutans
Eliava Phage Institute Georgia Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus sanguis, Streptococcus salivarius, Enterococcus spp. Staphylococcal, SES, FERSISI, INTESTI, PYO Bacteriophages Natural phages and personalized phage cocktails N/A Largest phage therapy center that works on various number of infections caused by resistant pathogens
Intralytix Pharmaceuticals USA Staphylococcus aureus PhagoBioDerm Natural phage FDA Targeting the leg ulcers caused by Staphylococcus aureus, they have successful completed the phase I clinical trials
Adaptive Phage Therapeutics USA Staphylococcus aureus N/A Personalized phage cocktails Not approved by FDA, currently they are treating patient on eIND The host range of the phages (deposited in phage bank) is determined by calorimetric method against the pathogen isolated from the patients and given in the cocktail for therapy
Locus Biosciences USA Clostridium difficile crPhage™ CRISPR/Cas engineered phage FDA To treat recurrent Clostridium difficile infection (CDI)
Phagelux China Staphylococcus aureus,Staphylococcus epidermidis PL-01-SS,PL-03-BM,PL-06-FC,PL-01-SZ, Natural phages, endolysin N/A For treatment of infection caused by Staphylococcus spp. such as burn wounds, ulcers, acne, eczema and implant related. They are in the pre-clinical studies of the phage products
Phagomed Austria Staphylococcus aureus N/A Natural phage cocktails Austrian Research Promotion Agency (FFG) To treatment biofilms and implant associated infections
Microgen Russia Staphylococcus aureus, Streptococcus spp. Sextaphag®, Complex pyobacteriophage, Streptococcus bacteriophage Natural phage cocktails N/A To treat various number of infections caused by S. aureus and Streptococcus spp. in combination with other phages of Gram-negative pathogens
GangaGen India Staphylococcus aureus P128 (ectolysin) Phage-encoded endolysin N/A They are in the Phase II clinical trial of lysin against MRSA
ContraFect USA Staphylococcus aureus
Streptococcus pneumonia
Enterococcus faecalis
Group B streptococcus
Bacillus anthracis
CF-301 (Exebacase),
Phage-encoded endolysin FDA To treat endocarditis, prosthetic joint infections caused by MRSA and also against other Gram-positive bacterial infections. Lysin is used in combination with SOC antibiotic (e.g., vancomycin, daptomycin) that is found to enhance the efficacy. Exebacase is the first lysin to enter phase III clinical trial in USA
  1. N/A information not available, FDA Food and Drug Administration, eIND emergency investigational new drug